A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania-Reference-Cited by-同舟云学术

A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania

Published:2022-06-23 Issue: Volume:28 Page:
ISSN:1643-3750
Container-title:Medical Science Monitor
language:en
Short-container-title:Med Sci Monit

Author:

Bacinschi Xenia¹,Popescu Gabriel Cristian²,Zgura Anca¹,Gales Laurentia³,Rodica Anghel¹,Mercan Adriana⁴,Serban Dragos⁵,Haineala Bogdan⁶,Toma Letitia⁴,Iliescu Laura⁴

Affiliation:

1. Department of Oncology-Radiotherapy, Alexandru Trestioreanu Institute of Oncology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

2. General Surgery Department, Bagdasar Arseni Clinical Emergency Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

3. Department of Oncology-Radiotherapy, Alexandru Trestioreanu Institute of Oncology, Carol Davila University of Medicine and Pharmacy, Bucharest, Russian Federation

4. Department of Internal Medicine, Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

5. Department of General Surgery, Emergency University Bucharest Romania, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

6. Department of Urology, Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

Publisher

International Scientific Information, Inc.

Subject

General Medicine

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Viral proteases as therapeutic targets;Molecular Aspects of Medicine;2022-12

2. Multiple drugs;Reactions Weekly;2022-09-03